Increased demand, primarily driven by seasonal illnesses like Lyme disease and respiratory infections, frequently strains supply chains. This surge in prescriptions often outpaces manufacturing capacity, leading to shortages.
Manufacturing challenges, including raw material shortages or production facility issues, can significantly impact doxycycline availability. These disruptions can range from minor setbacks to major production halts, directly affecting supply.
Regulatory hurdles and inspections can temporarily halt or slow down doxycycline production. Compliance requirements and unexpected delays in approvals add to the complexity of maintaining consistent supply.
Generic competition affects pricing and production incentives. Price pressures may discourage manufacturers from investing in increased production capacity if profit margins are insufficient.
Distribution network bottlenecks further complicate matters. Issues with transportation, warehousing, and logistics can delay delivery of the medication to pharmacies, exacerbating shortages.
Strategic stockpiling by hospitals and healthcare systems, in anticipation of high demand periods, can also reduce the medication available to the general public.
